News

Nasdaq3y
Has Catalyst Biosciences (CBIO) Outpaced Other Medical Stocks This Year? - Nasdaq
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Catalyst Biosciences, Inc. (CBIO) been one of those ...
Business Insider4y
Catalyst Biosciences Announces First Patient Dosed in Marzeptacog Alfa (Activated) Phase 1/2 Study in Factor VII Deficiency, Glanzmann Thrombasthenia and ... - Markets Insider
SOUTH SAN FRANCISCO, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the initiation of dosing in the Company's Phase 1/2 study (MAA-202) of ...
Business Insider8y
Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in EuropePositive opinion issued by EMA Committee for Orphan Medicinal Products for ... - Markets Insider
SOUTH SAN FRANCISCO, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
Benzinga.com2y
CATALYST BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Catalyst Biosciences, Inc. - CBIO - Catalyst ... - Benzinga
NEW ORLEANS, March 9, 2023 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating Catalyst Biosciences ...